Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Opinion Statement: There has been rapid progress in the use of targeted therapies for ALK-positive which has led to improve dramatically PFS and OS in the metastatic ALK-rearranged NSCLC patients. There are several molecules now available (crizotinib, ceritinib, brigatinib, alectinib, and lorlatinib...
| Publicado en: | Current Treatment Options in Oncology Vol. 20; no. 10 |
|---|---|
| Autores principales: | , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Oct2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138611249&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 138611249 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Oct2019 vid: 20 iid: 10 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 138611249 138611249 NLM31482479 138611249 10.1007/s11864-019-0675-9 NLM31482479 138611249 ppct: 1 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. aug: au: Friedlaender, Alex Banna, Giuseppe Patel, Sandip Addeo, Alfredo affil: Oncology Department, Geneva University Hospital (CH), Rue Gabrielle-Perret-Gentil 4, 1205, Genève, Switzerland sug: subj: Carcinoma, Non-Small-Cell Lung Diagnosis Lung Neoplasms Diagnosis Lung Neoplasms Etiology Lung Neoplasms Therapy Carcinoma, Non-Small-Cell Lung Etiology Chromosome Aberrations Carcinoma, Non-Small-Cell Lung Therapy Disease Management Protein Kinase Inhibitors Therapeutic Use Neoplasm Staging Drug Therapy Methods Molecular Diagnostic Techniques Neoplasm Metastasis Protein Kinase Inhibitors Pharmacodynamics Scales ab: Opinion Statement: There has been rapid progress in the use of targeted therapies for ALK-positive which has led to improve dramatically PFS and OS in the metastatic ALK-rearranged NSCLC patients. There are several molecules now available (crizotinib, ceritinib, brigatinib, alectinib, and lorlatinib) and others in development. Such an improvement in treatment efficacy has even more highlighted the importance of an adequate identification of ALK alterations. Efficient and easily accessible testing tools are required to identify eligible patients in a timely fashion. Different methods for detecting ALK+ NSCLC patients are now available, with fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) currently representing validated diagnostic techniques for the initial assessment of ALK status. Furthermore the widespread use of next-generation sequencing to detect other possible different activating mutations has allowed to identify individual ALK fusion variants. Several more expensive and time-consuming methods are also available nowadays which have the advantage to detect even rarer uncommon ALK fusion variants and mutations in tumour or blood samples. A review of the evolving testing-treatment landscape is needed to highlight the importance of properly diagnosing and treating this group of patients. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|